Literature DB >> 11569940

Treatment of gynecomastia.

U Gruntmanis1, G D Braunstein.   

Abstract

Gynecomastia is a common problem during puberty as well as later adulthood, and is caused by hormonal imbalance at the breast tissue level. Various medications and medical conditions can cause gynecomastia and when the drug is discontinued or medical condition cured, it will frequently resolve. Medical therapy can be tried for patients with persistent gynecomastia associated-tenderness or social embarrassment prior to contemplating surgical removal of the breast tissue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11569940

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  4 in total

1.  Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.

Authors:  A Nordenström; S F Ahmed; E van den Akker; J Blair; M Bonomi; C Brachet; L H A Broersen; H L Claahsen-van der Grinten; A B Dessens; A Gawlik; C H Gravholt; A Juul; C Krausz; T Raivio; A Smyth; P Touraine; D Vitali; O M Dekkers
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

2.  Surgical Strategies in the Treatment of Gynecomastia Grade I-II: The Combination of Liposuction and Subcutaneous Mastectomy Provides Excellent Patient Outcome and Satisfaction.

Authors:  Lars Schröder; Christian Rudlowski; Gisela Walgenbach-Brünagel; Claudia Leutner; Walther Kuhn; Klaus-Jürgen Walgenbach
Journal:  Breast Care (Basel)       Date:  2015-04-07       Impact factor: 2.860

3.  Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy.

Authors:  Prasanth N Surampudi; Christina Wang; Ronald Swerdloff
Journal:  Int J Endocrinol       Date:  2012-03-14       Impact factor: 3.257

4.  Double blind randomized placebo-controlled trial on the effects of testosterone supplementation in elderly men with moderate to low testosterone levels: design and baseline characteristics [ISRCTN23688581].

Authors:  Hamid Reza Nakhai Pour; Marielle H Emmelot-Vonk; Marja Sukel-Helleman; Harald J J Verhaar; Diederick E Grobbee; Yvonne T van der Schouw
Journal:  Trials       Date:  2006-08-03       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.